Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Klaus Fruh
Oregon Health & Science University, Department: None
Should you be removed from our database? Contact us at [email protected]. Read more below.
Vir Biotechnologies, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Please see pdf uploaded
Development of Immunogenicity- and Efficacy-Optimized CMV Vectors for an HIV/AIDS Vaccine
Overall Program Relevance Recent epidemiologic analysis has indicated that even a 70% effective HIV/AIDS vaccine would reduce the annual incidence of new HIV infections by nearly 80% over that of the best-case implementation of anti- retroviral treatment and other non-vaccine prevention measures. Our Cytomegalovirus (CMV) vector-based ?effector memory? T cell vaccine is one of very few vaccine concepts in clinical development today with demonstrated efficacy in stringent nonhuman primate challenge models. The work proposed in this application will be essential to effectively translate this pre-clinical efficacy into a safe and effective HIV/AIDS vaccine for people. �
Filed on January 24, 2018.
Tell us what you know about Klaus Fruh's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Klaus Fruh”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnologies, Inc. | $150,000 - $199,999 |
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. | $0 - $4,999 |
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. | $0 - $4,999 |
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnologies, Inc. | $0 - $4,999 |
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. | $150,000 - $199,999 |
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnologies, Inc. | $0 - $4,999 |
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. | $150,000 - $199,999 |
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. (formerly called TomegaVax, Inc.) | $150,000 - $199,999 |
| Klaus Fruh | Oregon Health & Science University | Conflict of Interest | Vir Biotechnology, Inc. | $150,000 - $199,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.